can semaglutide cause stomach ulcers Ozempic: is a GLP-1 receptor agonist used for type 2 diabetes and cardiovascular risk reduction in selected patients, commonly causing nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite, and weight loss GLP 1 Weight Loss Drugs

The following table describes GLP-1 receptor agonists, their dosing frequency and key pharmacokinetic parameters: Cautions and Contraindications Adverse Effects Acute pancreatitis (rare) Injection site reactions Gastrointestinal disturbances (nausea, vomiting, diarrhoea dehydration and possible renal impairment) Increase in pancreatic enzymes: lipase and amylase (dulaglutide, tirzepatide and semaglutide) Cholecystitis and cholelithiasis Delayed gastric emptying (semaglutide, exenatide, dulaglutide, tirzepatide (diminishes over time)) Increased heart rate Diabetic retinopathy complications (semaglutide, particularly in insulin-treated patients with known diabetic retinopathy) Interactions GLP-1 receptor agonists do not interact via cytochrome P450 , but delayed gastric emptying may alter drug absorption

First-time prescribing of ADMs decreased in December 2024 relative to September 2024 (-13.81%), as did first-time prescribing of AOMs (-8.10%)

doi: 10.1098/rstb.2006.1860 12 HirschbergAL

Tirzepatide acts as a GLP-1 receptor agonist (like semaglutide), and it also acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist